Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$323.90 7.73 (2.45)%
Market Cap 34.27B
04/26/18 1:09 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Regeneron Pharmaceuticals Q1 2018 Earnings Conference Call
May 3, 2018 | 8:30 AM ET
J.P. Morgan 2018 Spring Biotech Conference Call Series
May 8, 2018 | 10:00 AM ET